JonesTrading analyst Soumit Roy has maintained their bullish stance on OKUR stock, giving a Buy rating on March 11.
Soumit Roy’s rating is based on OnKure Therapeutics’ promising developments and strategic plans for their primary asset, OKI-219. The company is gearing up for a significant year in 2025, with plans to validate OKI-219 both as a standalone treatment and in combination with existing therapies for HR+/HER2- breast cancer. This includes the anticipated release of additional data from their Phase 1 PIKture-01 trial in the second half of 2025, which could serve as a pivotal moment for the company’s progress.
Furthermore, OnKure’s strategy to nominate a pan-mutant PI3Kα inhibitor with enhanced efficacy towards specific mutations by the second quarter of 2025 is seen as a move to capture a larger market share. This initiative positions OnKure in direct competition with other notable players in the field, potentially expanding their market reach. The absence of dose-limiting toxicities in ongoing trials also supports a positive outlook, contributing to the Buy rating.
According to TipRanks, Roy is an analyst with an average return of -23.0% and a 17.53% success rate. Roy covers the Healthcare sector, focusing on stocks such as Chimerix, Precision BioSciences, and Oric Pharmaceuticals.
In another report released on March 11, Oppenheimer also maintained a Buy rating on the stock with a $30.00 price target.